drugset / Trial / NCT01135368

Safety and Efficacy of Lansoprazole in Patients With Reflux Disease

NCT01135368

Phase 4 Completed 506 enrolled Takeda
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to measure the safety, efficacy and quality of life of lansoprazole in patients with reflux disease over a five year period.

Timeline

Start
2002-06
Primary completion
2008-09
Completion
2008-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Lansoprazole Other / unclassified 15 mg Oral
Subject Lansoprazole Other / unclassified 30 mg Oral